Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:59:09 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Z:GSK - GSK PLC SPON ADS EACH REP 2 ORD SHS - http://www.gsk.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GSK - Z4.038.50·43.240.139.75+0.481.21,623.963,2409,93439.37  39.76  39.3743.84  33.3319:48:38Mar 1615 min RT 2¢

Recent Trades - Last 10 of 9934
Time ETExPriceChangeVolume
19:48:38Z39.710.441
19:20:28Z39.730.461
19:00:10Z39.850.5814
18:38:47Z39.710.441
18:07:04Z39.710.445
17:20:27Z39.610.341
17:12:26Z39.760.491
17:04:31Z39.840.5725
16:53:00Z39.750.4832,681
16:19:46Z39.750.485

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-16 08:00U:GSKNews ReleasePositive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
2024-03-07 12:00U:GSKNews ReleaseGSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
2024-02-08 07:00U:GSKNews ReleaseAlector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer ¢ € ™s Disease
2024-02-07 16:01U:GSKNews Release23andMe Reports Third Quarter Fiscal 2024 Financial Results
2024-02-07 07:00U:GSKNews ReleaseFDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
2024-02-06 07:00U:GSKNews ReleaseGSK ¢ € ™s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
2024-01-24 08:00U:GSKNews ReleaseElegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen ¢ € ™s Cell-Free DNA Production Technology
2024-01-09 05:52U:GSKNews ReleaseGSK Enters Agreement to Acquire Aiolos Bio
2023-12-12 08:00U:GSKNews ReleaseGSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
2023-11-13 08:00U:GSKNews ReleaseGSK and Queer Eye ¢ € ™s Thom Filicia Partner on Blood Cancer Awareness Initiative
2023-10-30 08:00U:GSKNews Release23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
2023-10-27 07:00U:GSKNews ReleaseAlector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
2023-10-25 07:00U:GSKNews ReleaseNew Data for AREXVY, GSK ¢ € ™s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
2023-10-12 09:00U:GSKNews ReleaseGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
2023-09-15 19:26U:GSKNews ReleaseOjjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
2023-09-05 08:00U:GSKNews ReleaseGSK and Earvin ¢ € œMagic ¢ €  Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
2023-08-17 08:00U:GSKNews ReleaseGSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
2023-07-31 14:42U:GSKNews ReleaseJemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
2023-07-13 08:23U:GSKNews ReleaseGSK is first to ship influenza vaccine doses for the 2023-24 flu season in US
2023-06-28 10:57U:GSKNews ReleaseStock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health